112 related articles for article (PubMed ID: 35989064)
1. Clinical characteristics of patients with COVID-19 vaccine-related pneumonitis: a case series and literature review.
Park JY; Kim JH; Park S; Hwang YI; Kim HI; Jang SH; Jung KS; Kim YK; Kim HA; Lee IJ
Korean J Intern Med; 2022 Sep; 37(5):989-1001. PubMed ID: 35989064
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey.
Yoo H; Kim SY; Park MS; Jeong SH; Park SW; Lee HL; Lee HK; Yang SH; Jegal Y; Yoo JW; Lee J; Kang HK; Choi SM; Park J; Kim YW; Song JW; Park JH; Choi WI; Choi HS; Park C; Park JW; Chung MP
J Korean Med Sci; 2023 Apr; 38(14):e106. PubMed ID: 37038643
[TBL] [Abstract][Full Text] [Related]
3. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
6. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Min YG; Hong YH; Song TJ
J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
Heo JY; Seo YB; Kim EJ; Lee J; Kim YR; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
Front Immunol; 2022; 13():975363. PubMed ID: 36119092
[TBL] [Abstract][Full Text] [Related]
8. US Evaluation of Axillary Lymphadenopathy Following COVID-19 Vaccination: A Prospective Longitudinal Study.
Ha SM; Chu AJ; Lee J; Kim SY; Lee SH; Yoen H; Cho N; Moon WK; Chang JM
Radiology; 2022 Oct; 305(1):46-53. PubMed ID: 35471107
[TBL] [Abstract][Full Text] [Related]
9. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Baldolli A; Fournier A; Verdon R; Michon J
Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
[TBL] [Abstract][Full Text] [Related]
10. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
[TBL] [Abstract][Full Text] [Related]
11. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
13. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
Montgomery J; Ryan M; Engler R; Hoffman D; McClenathan B; Collins L; Loran D; Hrncir D; Herring K; Platzer M; Adams N; Sanou A; Cooper LT
JAMA Cardiol; 2021 Oct; 6(10):1202-1206. PubMed ID: 34185045
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
16. Temporal association between COVID-19 vaccination and Raynaud's phenomenon: A case series.
Lisy M; Urban N; Brunner-Ziegler S; Weber B; Bauer WM; Dassler E; Koppensteiner R; Handisurya A
Hum Vaccin Immunother; 2023 Dec; 19(1):2199653. PubMed ID: 37067070
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
18. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
19. Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection.
Alfaleh A; Alkattan A; Alzaher A; Radwan N; Mahmoud N; Alageel A; Alhabib D; Alsalameen E; Sagor K; Haji A; Alfaifi A; Alabdulkareem K; Ibrahim M
Clin Drug Investig; 2022 Oct; 42(10):799-806. PubMed ID: 36040662
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.
Dag Berild J; Bergstad Larsen V; Myrup Thiesson E; Lehtonen T; Grøsland M; Helgeland J; Wolhlfahrt J; Vinsløv Hansen J; Palmu AA; Hviid A
JAMA Netw Open; 2022 Jun; 5(6):e2217375. PubMed ID: 35699955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
